339 related articles for article (PubMed ID: 27283767)
21. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Alqahtani A; Choucair K; Ashraf M; Hammouda DM; Alloghbi A; Khan T; Senzer N; Nemunaitis J
Future Sci OA; 2019 Mar; 5(3):FSO372. PubMed ID: 30906568
[TBL] [Abstract][Full Text] [Related]
22. Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors.
Wadhwa E; Nicolaides T
Cureus; 2016 May; 8(5):e620. PubMed ID: 27382528
[TBL] [Abstract][Full Text] [Related]
23. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Ramadoss M; Mahadevan V
Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
[TBL] [Abstract][Full Text] [Related]
24. BET inhibitors in cancer therapeutics: a patent review.
Ghoshal A; Yugandhar D; Srivastava AK
Expert Opin Ther Pat; 2016; 26(4):505-22. PubMed ID: 26924192
[TBL] [Abstract][Full Text] [Related]
25. HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.
Lin X; Huang X; Uziel T; Hessler P; Albert DH; Roberts-Rapp LA; McDaniel KF; Kati WM; Shen Y
Mol Cancer Ther; 2017 Feb; 16(2):388-396. PubMed ID: 27903752
[TBL] [Abstract][Full Text] [Related]
26. Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue.
Stratikopoulos EE; Parsons RE
Clin Cancer Res; 2016 Jun; 22(11):2605-10. PubMed ID: 27250929
[TBL] [Abstract][Full Text] [Related]
27. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
Mao W; Ghasemzadeh A; Freeman ZT; Obradovic A; Chaimowitz MG; Nirschl TR; McKiernan E; Yegnasubramanian S; Drake CG
J Immunother Cancer; 2019 Oct; 7(1):277. PubMed ID: 31653272
[TBL] [Abstract][Full Text] [Related]
29. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
30. Bromodomain inhibitors: what does the future hold?
Bhattacharya S; Piya S; Borthakur G
Clin Adv Hematol Oncol; 2018 Jul; 16(7):504-515. PubMed ID: 30067623
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
[TBL] [Abstract][Full Text] [Related]
32. Role of bromodomain and extraterminal (BET) proteins in prostate cancer.
Mandl A; Markowski MC; Carducci MA; Antonarakis ES
Expert Opin Investig Drugs; 2023 Mar; 32(3):213-228. PubMed ID: 36857796
[TBL] [Abstract][Full Text] [Related]
33. Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.
Cooper JM; Patel AJ; Chen Z; Liao CP; Chen K; Mo J; Wang Y; Le LQ
Clin Cancer Res; 2019 Jun; 25(11):3404-3416. PubMed ID: 30796033
[TBL] [Abstract][Full Text] [Related]
34. Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers.
Nguyen MV; Loof L; Falchook GS
J Immunother Precis Oncol; 2020 Feb; 3(1):16-22. PubMed ID: 35756176
[TBL] [Abstract][Full Text] [Related]
35. Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies.
Bertoni F; Stathis A
Curr Opin Hematol; 2019 Jul; 26(4):273-280. PubMed ID: 31116107
[TBL] [Abstract][Full Text] [Related]
36. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
[TBL] [Abstract][Full Text] [Related]
37. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers.
Sun HY; Du ST; Li YY; Deng GT; Zeng FR
World J Gastrointest Oncol; 2022 Jan; 14(1):75-89. PubMed ID: 35116104
[TBL] [Abstract][Full Text] [Related]
38. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
[TBL] [Abstract][Full Text] [Related]
39. Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics.
Cai M; Dong J; Li H; Qin JJ
Curr Med Chem; 2022; 29(25):4391-4409. PubMed ID: 35152859
[TBL] [Abstract][Full Text] [Related]
40. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
Ma Y; Wang L; Neitzel LR; Loganathan SN; Tang N; Qin L; Crispi EE; Guo Y; Knapp S; Beauchamp RD; Lee E; Wang J
Clin Cancer Res; 2017 Apr; 23(8):2027-2037. PubMed ID: 27678457
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
